Gilead Sciences, Inc. (NASDAQ:GILD) to Post Q3 2025 Earnings of $2.06 Per Share, Zacks Research Forecasts

Gilead Sciences, Inc. (NASDAQ:GILD) – Stock analysts at Zacks Research upped their Q3 2025 earnings per share estimates for shares of Gilead Sciences in a report issued on Monday, June 3rd. Zacks Research analyst E. Bagri now expects that the biopharmaceutical company will earn $2.06 per share for the quarter, up from their previous forecast of $2.05. The consensus estimate for Gilead Sciences’ current full-year earnings is $3.75 per share. Zacks Research also issued estimates for Gilead Sciences’ Q4 2025 earnings at $1.86 EPS and FY2025 earnings at $7.17 EPS.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, topping the consensus estimate of ($1.49) by $0.17. The company had revenue of $6.69 billion for the quarter, compared to the consensus estimate of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period last year, the firm earned $1.37 EPS.

GILD has been the topic of several other reports. Wells Fargo & Company lowered their target price on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a research note on Monday, March 4th. Oppenheimer reissued an “outperform” rating and issued a $105.00 target price on shares of Gilead Sciences in a research note on Friday, April 19th. HSBC upgraded shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price target for the company in a report on Wednesday, April 24th. Maxim Group cut their price target on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a report on Wednesday, May 1st. Finally, TD Cowen cut their price target on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a report on Friday, April 26th. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $83.69.

Gilead Sciences Trading Up 1.3 %

GILD stock opened at $64.70 on Thursday. The company’s 50-day simple moving average is $66.66 and its 200-day simple moving average is $73.71. The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31. Gilead Sciences has a 52-week low of $62.07 and a 52-week high of $87.86. The firm has a market cap of $80.61 billion, a P/E ratio of 179.72, a PEG ratio of 1.28 and a beta of 0.20.

Institutional Investors Weigh In On Gilead Sciences

A number of large investors have recently added to or reduced their stakes in the company. Tompkins Financial Corp lifted its position in shares of Gilead Sciences by 223.1% in the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 241 shares during the last quarter. Fortitude Family Office LLC bought a new stake in shares of Gilead Sciences during the 4th quarter worth about $29,000. Private Wealth Management Group LLC bought a new stake in shares of Gilead Sciences during the 4th quarter worth about $29,000. Palisade Asset Management LLC bought a new stake in shares of Gilead Sciences during the 1st quarter worth about $29,000. Finally, Sachetta LLC bought a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $30,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the sale, the insider now owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be paid a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 4.76%. The ex-dividend date of this dividend is Friday, June 14th. Gilead Sciences’s dividend payout ratio is currently 855.56%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.